Abemaciclib

Phase 1Recruiting

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Retroperitoneal Sarcoma

Conditions

Retroperitoneal Sarcoma

Trial Timeline

Mar 19, 2025 → Mar 3, 2029

NCT ID

NCT06025747

About Abemaciclib

Abemaciclib is a phase 1 stage product being developed by Eli Lilly for Retroperitoneal Sarcoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06025747. Target conditions include Retroperitoneal Sarcoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02792725	Pre-clinical	Completed	—	—	Metastatic Breast Cancer
NCT03763604	Pre-clinical	Completed	—	—	Metastatic Breast Cancer
NCT06025747	Phase 1	Recruiting	Mar 19, 2025	Mar 3, 2029	Retroperitoneal Sarcoma
NCT06678269	Phase 1	Recruiting	Nov 15, 2024	Nov 30, 2028	Metastatic Breast Cancer
NCT04003896	Phase 2	Terminated	Sep 24, 2021	Aug 15, 2023	Biliary Tract Carcinoma
NCT04408924	Phase 2	Completed	Jan 20, 2021	Jun 2, 2023	Metastatic Castration-Resistant Prostate Cancer
NCT04681768	Pre-clinical	Completed	Dec 22, 2020	Apr 1, 2025	Breast Cancer/ Metastatic Breast Cancer
NCT03891784	Phase 2	Active	Oct 31, 2019	Jul 1, 2026	Advanced Digestive System Neuroendocrine Neoplasm
NCT03837821	Phase 1	Active	Feb 5, 2019	Dec 1, 2026	Bladder Cancer
NCT03339843	Phase 2	Completed	Dec 19, 2018	Dec 20, 2023	Esophageal Adenocarcinoma
NCT03703466	Phase 2	Completed	Nov 28, 2018	Mar 9, 2023	Metastatic Breast Cancer
NCT03310879	Phase 2	Recruiting	Nov 21, 2017	Sep 30, 2026	Cancer
NCT02919696	Phase 1	Completed	Aug 7, 2017	Sep 3, 2019	Advanced Cancer
NCT03130439	Phase 2	Terminated	May 26, 2017	Jan 30, 2022	Breast Cancer
NCT02981940	Phase 2	Active	Feb 9, 2017	Jun 30, 2026	Glioblastoma
NCT02846987	Phase 2	Active	Jul 1, 2016	Jul 1, 2026	Sarcoma
NCT02482935	Phase 1	Completed	Jun 1, 2015	Sep 1, 2015	Healthy
NCT02308020	Phase 2	Completed	Apr 20, 2015	Nov 8, 2019	Breast Cancer
NCT02387814	Phase 1	Completed	Mar 1, 2015	Aug 1, 2015	Hepatic Insufficiency
NCT02102490	Phase 2	Completed	Jun 10, 2014	Oct 22, 2018	Metastatic Breast Cancer

Other Products from Eli Lilly

Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Approved

Olanzapine + PlaceboApproved

exenatide and sitagliptin + exenatide and placeboApproved

Tirzepatide + PlaceboApproved

tadalafilApproved